Kashiv BioSciences, LLC, a globally integrated biopharmaceutical company, has appointed Dr. Sandeep Nilkanth Athalye as its new Global Chief Executive Officer. With over 20 years of experience in strategic and operational roles within the pharmaceutical industry, Dr. Athalye will lead company operations and drive growth across key markets, including the U.S., Europe, and Asia. His previous leadership positions include tenures at Biocon Biologics, Boehringer Ingelheim, Novartis, and Schering-Plough Research Institute. He is well-regarded for his innovative, patient-centric strategies and dedication to sustainable growth. Dr. Athalye’s expertise in clinical development, regulatory strategy, and R&D equips him to guide Kashiv into its next growth phase, leveraging his skills to create collaborative environments and build high-performing teams that deliver exceptional results.
Chirag and Chintu Patel, Co-Founders and Board Members of Kashiv BioSciences, expressed their enthusiasm, saying, “We are thrilled to welcome Dr. Athalye to Kashiv. His appointment comes at a crucial time as we look to accelerate our growth in the expanding biosimilars market. We are confident that his industry knowledge and leadership will be key to realizing Kashiv’s ambitious global vision.”
In response, Dr. Athalye remarked, “Kashiv is an ambitious biosimilars company with a mission to provide affordable and accessible biosimilars worldwide. Our objective is to become a top player in the biosimilars space, backed by a differentiated pipeline and cutting-edge manufacturing and R&D facilities in the U.S. and India. I am excited about the opportunity to harness technology and innovation to position Kashiv as a leading developer of biologics.”
Dr. Athalye holds an MBBS in Medicine from Bharati Vidyapeeth, an MS in Clinical Pharmacology from The University of Toledo, and an MBA in BioPharma Innovation from Rutgers University.
